Drug delivery methods, structures, and compositions for nasolacrimal system
An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.
1. A method for treating dry eye with a punctal plug, the method comprising:
placing the punctal plug in a lacrimal canaliculus of an eye in need of treatment for dry eye, wherein the punctal plug remains in place for a period of at least one week, wherein the punctal plug comprises;
a silicone plug body comprising a drug insert
the drug insert comprising:
a drug core comprising a therapeutic agent and a polymeric matrix, wherein a distal end of the drug core is sealed with a medical grade adhesive; and
an impermeable sheath body partially covering the drug core, wherein the sheath body is configured to provide an exposed proximal end of the drug core in direct contact with tear fluid that releases therapeutic agent to the eye when the punctal plug is placed in the lacrimal canaliculus of a patient.
2. The method of claim 1 , wherein the therapeutic agent is selected from a lubricant, or a surfactant.
3. The method of claim 1 , wherein the therapeutic agent is cyclosporine.
4. The method of claim 1 , wherein the therapeutic agent is a corticosteroid.
5. The method of claim 1 , wherein a treatment period is from one week to 3 months.
6. The method of claim 1 , wherein the polymeric matrix comprises silicone, acrylate, polyethylene, polyurethane, polyester, polyglycolic acid (PGA), polylactic acid (PLA), poly(L-lactic acid) (PLLA), poly(L-glycolic acid) (PLGA), polyglycolide, poly-L-lactide, poly-D-lactide, poly(amino acids), polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, polyorthoesters, polyhydroxybutyrate, polyanhydride, polyphosphoester, poly(alpha-hydroxy acid) or combinations thereof.
7. The method of claim 1 , wherein the drug core further comprises one or more additives to increase or decrease solubility of the therapeutic agent for control of release of the therapeutic agent.
8. The method of claim 7 , wherein the one or more additives is selected from the group consisting of surfactants, tinuvin, salts and water.
9. A method for use in pre- or post-operative treatments with a punctal plug, the method comprising:
placing the punctal plug in a lacrimal canaliculus of an eye in need of pre- or post-operative treatments, wherein the punctal plug remains in place for a period of at least two days, wherein the punctal plug comprises;
a silicone plug body comprising a drug insert
the drug insert comprising:
a drug core comprising a therapeutic agent and a polymeric matrix, wherein a distal end of the drug core is sealed with a medical grade adhesive; and
an impermeable sheath body partially covering the drug core, wherein the sheath body is configured to provide an exposed proximal end of the drug core in direct contact with tear fluid that releases therapeutic agent to the eye when the punctal plug is placed in the lacrimal canaliculus of a patient.
10. The method of claim 9 , wherein the therapeutic agent is selected from a non-steroidal anti-inflammatory drug (NSAID), an anti-inflammatory agent, an immunosuppressive agent, a lubricant, a surfactant, a peptide, a protein, or an enzyme.
11. The method of claim 9 , wherein the therapeutic agent is a corticosteroid.
12. The method of claim 9 , wherein the therapeutic agent is dexamethasone.
13. The method of claim 9 , wherein a treatment period is from two days to one month.
14. The method of claim 9 , wherein the polymeric matrix comprises silicone, acrylate, polyethylene, polyurethane, polyester, polyglycolic acid (PGA), polylactic acid (PLA), poly(L-lactic acid) (PLLA), poly(L-glycolic acid) (PLGA), polyglycolide, poly-L-lactide, poly-D-lactide, poly(amino acids), polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, polyorthoesters, polyhydroxybutyrate, polyanhydride, polyphosphoester, poly(alpha-hydroxy acid) or combinations thereof.
15. The method of claim 9 , wherein the drug core further comprises one or more additives to increase or decrease solubility of the therapeutic agent for control of release of the therapeutic agent.
16. The method of claim 9 , wherein the drug core is configured to provide a burst dose of the therapeutic agent.